CLAIMS

1. An ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone.

2. The ophthalmic composition according to claim 1, comprising polyvinylpyrrolidone having a K value of 17 or more.

3. The ophthalmic composition according to claim 1 or 2, comprising polyvinylpyrrolidone having a K value of 17 to 90.

4. The ophthalmic composition according to any of claims 1 to 3, comprising polyvinylpyrrolidone having a K value of 30.

5. The ophthalmic composition according to any of claims 1 to 4, comprising polyvinylpyrrolidone having a K value of 90.

6. The ophthalmic composition according to any of claims 1 to 5, wherein concentration of polyvinylpyrrolidone is 0.0001 to 10% (w/v).

7. The ophthalmic composition according to any of claims 1 to 6, wherein the concentration of the diquafosol or a salt thereof is 0.0001 to 10% (w/v).

8. The ophthalmic composition according to any of claims 1 to 7, wherein the concentration of the diquafosol or a salt thereof is 0.01 to 5% (w/v).

9. The ophthalmic composition according to any of claims 1 to 8, wherein the concentration of the diquafosol or a salt thereof is 1 to 5% (w/v).

10. The ophthalmic composition according to any of claims 1 to 9, wherein the concentration of the diquafosol or a salt thereof is 3% (w/v).

11. The ophthalmic composition according to any of claims 1 to 10, wherein the ophthalmic composition is an eye drop.

12. The ophthalmic composition according to any of claims 1 to 11, wherein the ophthalmic composition is aqueous.

13. The ophthalmic composition according to any of claims 1 to 12, wherein the ophthalmic composition is a suspension-type or solution-type composition.

14. The ophthalmic composition according to any of claims 1 to 13, wherein the viscosity is 1 to 500 mPa·s at 25°C.

15. The ophthalmic composition according to any of claims 1 to 14, wherein the viscosity is 1 to 100 mPa·s at 25°C.

16. The ophthalmic composition according to any of claims 1 to 15, wherein the salt of diquafosol is diquafosol sodium.

17. The ophthalmic composition according to any of claims 1 to 16 for use in therapy.

18. Use of the ophthalmic composition according to any of claims 1 to 16 in the preparation of a medicament for prevention or treatment of dry eye.

19. The use according to claim 18, wherein the medicament is suitable for being instilled into an eye 1 to 6 times a day in a dose of 1 to 5 drops each time.

20. The use according to claim 18 or 19, wherein the medicament is suitable for being instilled into an eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

21. The use according to any of claims 18 to 20, wherein the medicament is suitable for being instilled into an eye 3 or 4 times a day in a dose of 1 or 2 drops each time.